Jeffrey S. Parkin

Array ( [id] => 18816039 [patent_doc_number] => 20230390378 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-07 [patent_title] => IMMUNOGENIC FORMULATION CONTAINING A MODIFIED BCG STRAIN EXPRESSING AN ANDESVIRUS PROTEIN (ANDV) USEFUL FOR PREVENTING AND TREATING HANTA-ANDV VIRUS INFECTIONS [patent_app_type] => utility [patent_app_number] => 18/247824 [patent_app_country] => US [patent_app_date] => 2021-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3366 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18247824 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18895201 [patent_doc_number] => 20240010686 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-11 [patent_title] => DNA CONSTRUCT FOR STABLY PRODUCING EMPTY CAPSIDS OF THE FOOT-AND-MOUTH DISEASE VIRUS IN MAMMALIAN CELLS; PROCESSES, USES, AND COMPOSITIONS THEREOF [patent_app_type] => utility [patent_app_number] => 18/252212 [patent_app_country] => US [patent_app_date] => 2021-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7781 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18252212 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17482192 [patent_doc_number] => 20220089696 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-24 [patent_title] => ARENAVIRUS MONOCLONAL ANTIBODIES AND USES [patent_app_type] => utility [patent_app_number] => 17/520338 [patent_app_country] => US [patent_app_date] => 2021-11-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17488 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 268 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17520338 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18842702 [patent_doc_number] => 20230405106 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-21 [patent_title] => CHIMERIC PROTEIN COMPRISING THE RECEPTOR BINDING DOMAIN OF THE CORONA VIRUS SPIKE PROTEIN AND COMPOSITIONS COMPRISING THEM [patent_app_type] => utility [patent_app_number] => 18/035254 [patent_app_country] => US [patent_app_date] => 2021-11-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20620 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18035254 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18877516 [patent_doc_number] => 20240000885 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-04 [patent_title] => COMPOSITIONS AND METHODS FOR TARGETING THE INTERACTION OF HOST MYO5B+D AND CORONAVIRUS M PROTEINS [patent_app_type] => utility [patent_app_number] => 18/251497 [patent_app_country] => US [patent_app_date] => 2021-11-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13962 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18251497 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17579218 [patent_doc_number] => 20220136073 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-05 [patent_title] => CHARACTERIZATION OF IMPURITIES IN ADENO-ASSOCIATED VIRUS (AAV) SAMPLES AND FORMULATION COMPOSITIONS TO STABILIZE AAV [patent_app_type] => utility [patent_app_number] => 17/516172 [patent_app_country] => US [patent_app_date] => 2021-11-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11181 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17516172 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18769452 [patent_doc_number] => 20230364216 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-16 [patent_title] => LENTIVIRAL VECTORS ENABLING ROUTING ANTIGENS TO MHC-II PATHWAY AND INDUCING CD4+ AND CD8+ T-CELL RESPONSES IN A HOST [patent_app_type] => utility [patent_app_number] => 18/030102 [patent_app_country] => US [patent_app_date] => 2021-10-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21389 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18030102 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18956542 [patent_doc_number] => 20240044869 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-08 [patent_title] => ASSAY FOR MEASURING POTENCY OF GENE THERAPY DRUG PRODUCT [patent_app_type] => utility [patent_app_number] => 18/031494 [patent_app_country] => US [patent_app_date] => 2021-10-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6178 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 177 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18031494 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17641969 [patent_doc_number] => 20220169707 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-02 [patent_title] => ANTIBODIES TARGETING HIV ESCAPE MUTANTS [patent_app_type] => utility [patent_app_number] => 17/500171 [patent_app_country] => US [patent_app_date] => 2021-10-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10795 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 103 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17500171 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18806963 [patent_doc_number] => 20230381296 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-30 [patent_title] => TEMPERATURE-SENSITIVE BETACORONAVIRUS STRAIN AND VACCINE [patent_app_type] => utility [patent_app_number] => 18/031570 [patent_app_country] => US [patent_app_date] => 2021-10-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13773 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 149 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18031570 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19447392 [patent_doc_number] => 20240307522 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-19 [patent_title] => COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF COVID-19 [patent_app_type] => utility [patent_app_number] => 18/248334 [patent_app_country] => US [patent_app_date] => 2021-10-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 69560 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18248334 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17519316 [patent_doc_number] => 20220105164 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-07 [patent_title] => Method for Restoring Immune Tolerance In Vivo [patent_app_type] => utility [patent_app_number] => 17/497354 [patent_app_country] => US [patent_app_date] => 2021-10-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18169 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 116 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17497354 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18754409 [patent_doc_number] => 20230357824 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-09 [patent_title] => EXTRACTION SOLUTION FOR PREPARING A BIOLOGICAL SAMPLE FOR AMPLIFICATION BASED PATHOGEN DETECTION [patent_app_type] => utility [patent_app_number] => 18/029538 [patent_app_country] => US [patent_app_date] => 2021-10-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37981 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -37 [patent_words_short_claim] => 105 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18029538 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17482632 [patent_doc_number] => 20220090136 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-24 [patent_title] => SIN NOMBRE VIRUS FULL-LENGTH M SEGMENT-BASED DNA VACCINES [patent_app_type] => utility [patent_app_number] => 17/492291 [patent_app_country] => US [patent_app_date] => 2021-10-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19717 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17492291 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19779542 [patent_doc_number] => 12228572 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-02-18 [patent_title] => Enhanced expression of polo-like kinase 3 (PLK3) in human immunodeficiency virus (HIV)-infected cells [patent_app_type] => utility [patent_app_number] => 18/292949 [patent_app_country] => US [patent_app_date] => 2021-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 18 [patent_no_of_words] => 3417 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18292949 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18752491 [patent_doc_number] => 20230355747 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-09 [patent_title] => COMPOUND FOR INCREASING EFFICACY OF VIRAL VECTORS [patent_app_type] => utility [patent_app_number] => 18/246117 [patent_app_country] => US [patent_app_date] => 2021-09-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46609 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 163 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18246117 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17368363 [patent_doc_number] => 20220023415 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-27 [patent_title] => ANTI COVID-19 THERAPIES USING NUCLEOCAPSID AND SPIKE PROTEINS [patent_app_type] => utility [patent_app_number] => 17/448033 [patent_app_country] => US [patent_app_date] => 2021-09-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8899 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17448033 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18895515 [patent_doc_number] => 20240011000 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-11 [patent_title] => RECOMBINANT PROTEINS WITH INCREASED SOLUBILITY AND STABILITY [patent_app_type] => utility [patent_app_number] => 18/044909 [patent_app_country] => US [patent_app_date] => 2021-09-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25038 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18044909 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17336060 [patent_doc_number] => 20220002391 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-06 [patent_title] => Broadly Neutralizing Anti-HIV Antibodies and Epitope Therefor [patent_app_type] => utility [patent_app_number] => 17/471573 [patent_app_country] => US [patent_app_date] => 2021-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19189 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17471573 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17520536 [patent_doc_number] => 20220106385 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-07 [patent_title] => USE OF MODIFIED HIV-1 FOR GENERATING FULLY HUMAN ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/470463 [patent_app_country] => US [patent_app_date] => 2021-09-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11254 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17470463 [rel_patent_id] =>[rel_patent_doc_number] =>)